Navigation Links
Genomic Health to Present Five New Studies at 32nd Annual San Antonio Breast Cancer Symposium
Date:12/4/2009

REDWOOD CITY, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center. Four of the studies analyze Oncotype DX®, the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.

Following are details for each embargoed session (all times are in Central Standard Time):

  • Thursday, December 10, 2009, 5:30 p.m. - 7:30 p.m.

Abstract #112

Poster discussion (Poster Discussion 1 and Reception): "Prediction of 10-year chemotherapy benefit and breast cancer-specific survival by the 21-gene Recurrence Score (RS) assay in node-positive, ER-positive breast cancer - An update of SWOG-8814 (INT0100)"

Presenter: Kathy S. Albain, M.D., Professor, Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Director, Breast Clinical Research Program, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.

Location: Ballroom A

  • Friday, December 11, 2009, 7 a.m. - 9 a.m.

Abstract: #2031

Poster presentation (Poster Session II): "Effect of 21-Gene Recurrence Score Results on Treatment Recommendations in Patients with Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer"

Presenter: Ruth Oratz, M.D., NYU School of Medicine, New York, NY

Location: Exhibit Halls A-B

  • Saturday, December 12, 2009, 5:30 p.m. - 7:3
    '/>"/>

SOURCE Genomic Health
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Los Angeles, CA (PRWEB) , ... July 28, ... ... Fox Sports entitled "A Breakdown of Mets' David Wright's Spinal Stenosis Injury" ... to the field. Wright’s spinal stenosis is acquired lumbar stenosis, brought on by ...
(Date:7/28/2015)... ... ... Most employers have been using multi-tier prescription drug plans for many years, ... increase in the use of 4-tier plans, which typically cover the highest cost drugs, ... expected to continue, according to UBA. , UBA’s survey finds that, since 2009, the ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... There has ... most people think of highways, bridges and railroads, often overlooked is the over ... our homes and buildings and into sewage treatment facilities. According to the American ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... for identifying Top Doctors, has based its selection process on the foundation of ... in their medical specialties, in any area of medicine and in any part ...
(Date:7/28/2015)... ... July 28, 2015 , ... Maryland Brain & Spine has adopted a ... it, more service offerings, updated treatment techniques, and additional state-of-the art online resources for ... minimally invasive surgical treatment of brain and spine conditions. , “Adding the word ...
Breaking Medicine News(10 mins):Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 2Health News:Spine Surgeon Weighs in on Uncertain Future Baseball Career Future for David Wright 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4
... Lower potassium levels in the blood may help explain why ... 2 diabetes as whites, according to a new study by ... part of diabetes prevention may someday prove as easy as ... mean people should run out and start taking potassium supplements," ...
... 2 (HealthDay News) -- Babies born to women who smoke ... have a congenital heart defect than are the offspring of ... increased risk ranged from 20 percent to 70 percent, varying ... that obstruct the flow of blood from the right side ...
... Reporter , TUESDAY, March 1 (HealthDay News) -- On ... Administration approves medical devices with too little oversight comes ... without being adequately tested on women, despite an agency ... heart valves, pacemakers, defibrillators and stents get implanted in ...
... The National Eye Institute (NEI) and Food and Drug ... functional vision-related endpoints for clinical trials of visual prostheses ... visual acuity, visual fields and contrast sensitivity. These assessments ... test outcomes. Today, functional vision outcomes ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, March 1 ... some people of white European descent who have type 2 diabetes. ... may prove a future target for treatments, among other benefits, say ... Journal of the American Medical Association . As with ...
... , TUESDAY, March 1 (HealthDay News) -- A new international ... States and elsewhere may be infected with human papillomavirus (HPV), ... tumors. The finding could help public health experts ... study authors say. "The incidence of genital HPV infection ...
Cached Medicine News:Health News:Potassium levels possible key to racial disparity in Type 2 diabetes 2Health News:Smoking During Early Pregnancy May Put Baby's Heart at Risk 2Health News:Heart Devices Not Tested Enough in Women: Study 2Health News:Heart Devices Not Tested Enough in Women: Study 3Health News:Visual prostheses: Symposium to explore combining functional endpoints 2Health News:Scientists Spot Another Gene Behind Type 2 Diabetes 2Health News:Half of U.S. Men Infected With HPV, Study Reveals 2
(Date:7/27/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... subscriptions from institutional and accredited investors for a ... of common stock and 3.35 million common stock ...
(Date:7/27/2015)... 27, 2015 Bloomage BioTechnology Corporation Limited ("Bloomage" ... cooperation with the South Korean BioTech Company Medytox Inc. ... Medybloom to develop and promote Type A Botulinum Toxin ... Medytox, the Botulinum Toxin brand, occupies ... the fourth company in the world successfully developed and ...
(Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 2DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering 3Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 2Bloomage (00963.HK) and Medytox Inc. set up a Joint Venture To Jointly Develop Botulinum Toxin Market in China 3Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3
... BEVERLY, Mass., March 8, 2011 Cellceutix Corporation (Pink ... has entered into a Confidential Disclosure Agreement (CDA) pertaining ... world,s largest pharmaceutical companies. Cellceutix CEO, ... to be signing a CDA on a compound before ...
... Inc. (Nasdaq: CPIX ), a specialty pharmaceutical ... announced fourth quarter and full year 2010 financial results. ... December 31, 2010, net revenue was $12.8 million, up 20% ... quarterly revenue growth was largely driven by 16% year-over-year growth ...
Cached Medicine Technology:Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
"Ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Complies with international standards of electrophysiology....
... Slit Lamp is the ideal instrument combination: in ... handy slit lamp to an indirect ophthalmoscope. ... anterior and posterior ocular segments, the HSO 10 ... in miniature. Outstanding benefits for your work include ...
... Analyzers Model 350 and Model 360 ... lensometry for your practice. ,Simple to ... gives fast and accurate lens neutralization ... lenses, contact lenses, polycarbonate and other ...
... contains a plunger style advance, or a ... for multiple use. The injector is made ... STAAR cartridges. These injectors are sold sterile, ... This system was designed specifically for easy ...
Medicine Products: